Partager
Back

GENZYME

SPOTLIGHT

€2,395 million(1) sales in 2011

The products and services offered by Genzyme are primarily for treatment of rare genetic lysosomal storage disorders. Genzyme offers enzyme replacement therapies, including in particular Cerezyme® (Gaucher disease), Fabrazyme® (Fabry disease), and Myozyme/Lumizyme® (Pompe disease).
In January 2012, the European Medicines Agency and the U.S. Food and Drug Administration approved the manufacturing plant in Framingham, Massachusetts (United States) for the production of Fabrazyme®.

(1) Consolidated from April 1st, 2011, at constant exchange rates.

Read more